Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Gastroenterology and hepatology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Barrett oesophagus and surveillance

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Barrett oesophagus itself is not an emergency, but new progressive dysphagia, food obstruction, haematemesis, melaena, substantial anaemia, persistent vomiting or weight loss needs urgent investigation rather than waiting for scheduled surveillance. A visible ulcer, nodule or cancer-suspicious lesion at endoscopy requires targeted biopsy or endoscopic resection planning and prompt upper-GI cancer MDT referral. Do not reassure from a recent non-dysplastic biopsy when new alarm symptoms have appeared.

Overview

Explain Barrett oesophagus risk accurately, deliver evidence-based surveillance and route dysplasia to expert endoscopic therapy without overtreating non-dysplastic disease.

Chronic gastro-oesophageal reflux can replace normal squamous lining with columnar mucosa. Endoscopic description should use recognised landmarks and Prague circumferential and maximal measurements, while histology establishes metaplasia and whether dysplasia is present. A slightly irregular Z-line or intestinal metaplasia confined to the gastric cardia should not be casually enrolled into lifelong Barrett surveillance. High-quality index endoscopy matters because segment length and visible lesions determine both risk and management.

Progression usually moves from non-dysplastic metaplasia through low-grade and high-grade dysplasia to adenocarcinoma, but many people never progress. Surveillance quality depends on careful mucosal cleaning, adequate inspection, targeted sampling of visible abnormalities and systematic Seattle biopsies. Dysplasia interpretation is difficult and should be confirmed by expert gastrointestinal pathologists. If active oesophagitis obscures assessment, acid suppression and repeat expert endoscopy may be safer than immediate ablation.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Gastroenterology and hepatologyOriginal SBA

Surveillance interval by length

A fit adult has a 4 cm segment of non-dysplastic Barrett oesophagus with intestinal metaplasia and elects surveillance. What interval matches current NICE guidance?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Gastroenterology and hepatology topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG231 Barrett monitoring and managementCurrent surveillance intervals, biopsy approach and dysplasia treatment recommendations.
  • BSG endorsed Barrett guidance resourceOfficial UK society endorsement of current NICE and European guidance replacing older BSG recommendations.
  • NICE CG184 reflux recommendationsAcid-suppression and alarm-feature framework relevant to Barrett care.
  • Omeprazole summary of product characteristicsLicensed adult reflux dosing and medicine safety information.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Management balances reflux symptoms and neoplasia risk. A PPI treats GORD or oesophagitis but should not be presented as guaranteed cancer prevention, while NICE specifically advises against aspirin solely for chemoprevention. Confirmed dysplasia and T1a early cancer increasingly receive endoscopic resection and ablation in specialist centres, preserving the oesophagus. More invasive cancer or unfavourable pathology requires the upper-GI cancer MDT. Surveillance intervals and treatment availability can vary by UK jurisdiction and local commissioned service.

Key points

  • Barrett oesophagus is endoscopically visible columnar-lined distal oesophagus confirmed histologically; document the gastro-oesophageal junction and circumferential and maximal extent consistently.
  • It increases oesophageal adenocarcinoma risk, but the absolute annual risk for an individual with non-dysplastic Barrett is low and should be explained without alarmism.
  • Surveillance aims to detect dysplasia or early cancer when endoscopic cure is possible; it is not a guarantee against cancer.
  • NICE recommends high-resolution white-light endoscopy with targeted inspection and Seattle-protocol biopsies when surveillance is appropriate.
  • For non-dysplastic Barrett, current NICE intervals are every two to three years for segments at least 3 cm and every three to five years for shorter segments with intestinal metaplasia.
  • Age, comorbidity, procedural fitness, segment length and patient preference determine whether surveillance benefit outweighs burden.
  • Inflammation can mimic dysplasia; optimise reflux control and obtain expert gastrointestinal pathology review before an irreversible treatment decision.
  • Visible lesions are characterised and generally resected endoscopically for accurate staging before ablation of remaining dysplastic Barrett mucosa.
  • NICE recommends radiofrequency ablation for low-grade dysplasia confirmed from biopsies at two separate endoscopies under the specified pathway.

Aetiology

01

Chronic gastro-oesophageal reflux

Repeated exposure of the distal oesophageal mucosa to refluxed acid and bile is the principal acquired driver of Barrett metaplasia.

02

Host susceptibility

Increasing age, male sex, central obesity, smoking and a family history of Barrett oesophagus or oesophageal adenocarcinoma increase susceptibility among people with reflux.

03

Anatomical reflux promoters

A hiatus hernia and impaired lower oesophageal sphincter function increase reflux burden, although neither alone establishes the diagnosis or predicts progression.

Pathophysiology

  1. 1
    Metaplastic adaptation

    Chronic reflux injury replaces vulnerable stratified squamous epithelium with acid-resistant columnar mucosa containing intestinal-type differentiation in eligible Barrett segments.

  2. 2
    Clonal progression

    Persistent injury and inflammation permit accumulating molecular abnormalities, allowing some metaplastic clones to progress through low-grade and high-grade dysplasia.

  3. 3
    Invasive transformation

    Dysplastic epithelium can breach the mucosa and develop into oesophageal adenocarcinoma, although most non-dysplastic Barrett oesophagus never reaches this stage.

  4. 4
    Patchy disease distribution

    Dysplasia and early cancer may be focal within a long segment, explaining why careful inspection, targeted lesion assessment and systematic biopsies are complementary.

Clinical features and red flags

Non-dysplastic Barrett

A clearly visible columnar-lined segment above the gastro-oesophageal junction is confirmed histologically without dysplasia, usually during endoscopy for reflux or another indication.

Indefinite for dysplasia

Reactive atypia cannot be reliably separated from dysplasia, often because inflammation or sampling limits interpretation; expert review and repeat examination after reflux optimisation are needed.

Confirmed low-grade dysplasiaRed flag

Expert pathology confirms low-grade change and the finding persists on the required separate endoscopic sampling, substantially increasing progression risk and prompting specialist ablation discussion.

High-grade dysplasia or intramucosal cancerRed flag

Marked architectural and cytological abnormality or T1a cancer requires prompt expert endoscopic staging and treatment, usually including resection of visible lesions.

Visible neoplastic lesionRed flag

A nodule, ulcer, depression, irregular mucosa or focal distortion within Barrett should be described and directed to expert endoscopic resection rather than sampled repeatedly without a plan.

New alarm symptoms during surveillanceRed flag

Progressive dysphagia, weight loss, bleeding or persistent vomiting overrides the calendar interval and triggers urgent diagnostic endoscopy or cancer assessment.

Investigations

  1. 01
    High-resolution white-light endoscopyFirst step
    Why
    Define landmarks, segment length, inflammation and visible neoplasia.
    Interpretation and limitations
    Record Prague C and M values, hiatus anatomy and any focal lesion. Adequate cleaning and inspection time matter more than a vague label of 'known Barrett'.
  2. 02
    Seattle-protocol biopsies
    Why
    Sample non-visible dysplasia systematically during surveillance.
    Interpretation and limitations
    Target visible abnormalities separately and then take systematic four-quadrant biopsies at the protocol interval. Poor adherence reduces the sensitivity of surveillance, especially in longer segments.
  3. 03
    Expert gastrointestinal pathology review
    Why
    Confirm dysplasia before treatment or shortened surveillance.
    Interpretation and limitations
    Inflammatory atypia and low-grade dysplasia have important interobserver variation. Management should follow the expert consensus grade, not an unreviewed community label.
  4. 04
    Endoscopic mucosal resection
    Why
    Obtain accurate staging and potentially cure a focal visible lesion.
    Interpretation and limitations
    Resection defines depth, differentiation, lymphovascular invasion and margins more reliably than forceps biopsy. Unfavourable pathology is referred to the cancer MDT.
  5. 05

Differential diagnosis

01

Irregular Z-line

A minimally irregular squamocolumnar junction without a qualifying visible Barrett segment should not be converted into a lifelong surveillance diagnosis.

02

Gastric cardia metaplasia

Intestinal metaplasia sampled below the gastro-oesophageal junction belongs to the gastric cardia and must not be mislabelled as oesophageal Barrett mucosa.

03

Reflux oesophagitis

Active inflammation can obscure landmarks and produce reactive atypia that resembles dysplasia; reassessment after acid suppression may clarify the diagnosis.

04

Established oesophageal cancer

Progressive dysphagia, weight loss, bleeding or a visible ulcerated or nodular lesion raises invasive malignancy rather than uncomplicated surveillance-stage Barrett oesophagus.

Management

01Surveillance entryConfirm that Barrett surveillance is appropriateFirst stepColumnar mucosa is reported at an index endoscopy.+
  1. 1Verify endoscopic landmarks, measured segment length and histological metaplasia, distinguishing true Barrett from an irregular Z-line or gastric-cardia sampling.
  2. 2Review dysplasia through expert pathology where present and ensure active inflammation or a visible lesion has not made the baseline examination unreliable.
  3. 3Discuss absolute risk, potential benefit, procedural burden, age, comorbidity and whether the person could undergo treatment if dysplasia were found.
  4. 4If surveillance is chosen, set the NICE interval from segment length and histology and provide alarm-symptom safety-netting that overrides the scheduled date.
02High-quality surveillanceInspect first, biopsy systematicallyA planned Barrett surveillance endoscopy is performed.+

Complications

01

Epithelial dysplasia

Low-grade or high-grade dysplasia marks clonal neoplastic progression and changes care from routine surveillance to expert confirmation and treatment planning.

02

Oesophageal adenocarcinoma

A minority of patients develop invasive adenocarcinoma, with curability strongly influenced by detection while disease remains superficial and localised.

03

Ulceration and bleeding

Severe reflux injury or neoplastic change can ulcerate the Barrett segment, causing pain, iron-deficiency anaemia, haematemesis or melaena.

04

Peptic stricture

Chronic inflammatory injury and scarring can narrow the distal oesophagus, producing progressive dysphagia that requires diagnostic assessment rather than routine surveillance.

Monitoring and follow-up

  • For non-dysplastic Barrett, schedule high-quality surveillance every two to three years for segments at least 3 cm and every three to five years for shorter eligible segments.
  • At each contact ask about progressive dysphagia, bleeding, vomiting and weight loss, arranging urgent diagnostic assessment rather than awaiting surveillance.
  • Record Prague length, Seattle-protocol completion, visible-lesion management, pathology grade and expert review in a traceable Barrett register.
  • Reassess whether surveillance remains beneficial when frailty, comorbidity, life expectancy or willingness to undergo treatment changes.
  • After endoscopic eradication therapy, follow the specialist schedule and monitor strictures, residual intestinal metaplasia, recurrent dysplasia and reflux control.

Special situations

Risk is real but small

Non-dysplastic Barrett increases relative cancer risk, yet most affected people never develop adenocarcinoma. Absolute-risk language supports proportionate decisions.

Length changes interval

Longer segments have greater progression risk and receive more frequent NICE surveillance than short-segment disease with intestinal metaplasia.

Pathology review changes management

A substantial proportion of community low-grade diagnoses are downgraded by experts, preventing unnecessary ablation and anxiety.

Resect before ablating

A visible lesion contains staging information. Ablating it first can destroy evidence needed to decide whether endoscopic treatment is curative.

Surveillance is conditional

It has little value when a patient could not or would not undergo treatment for detected neoplasia; shared review should continue over time.

Common pitfalls

  1. 01

    Enrolling an irregular Z-line into lifelong surveillance without secure endoscopic and histological criteria.

  2. 02

    Giving a fixed surveillance interval without considering segment length, age, comorbidity or treatment fitness.

  3. 03

    Accepting low-grade dysplasia without expert GI pathology confirmation and the NICE confirmation pathway.

  4. 04

    Ablating a visible nodule before endoscopic resection has established invasion depth and risk features.

  5. 05

    Starting aspirin solely as Barrett chemoprevention despite current NICE advice.

  6. 06

    Waiting for a routine surveillance date when new dysphagia, bleeding or weight loss has developed.

  • Do not offer aspirin solely to prevent Barrett progression; prescribe it only for a separate evidence-based cardiovascular or other indication.
    • Cross-sectional cancer staging
    Why
    Assess regional or distant disease when invasive cancer is suspected.
    Interpretation and limitations
    CT, PET-CT or endoscopic ultrasound is selected by the upper-GI cancer MDT after histological context; routine staging is unnecessary for uncomplicated non-dysplastic Barrett.
  • 06
    Full blood count and symptom assessment
    Why
    Identify bleeding or a presentation requiring urgent diagnostic rather than surveillance care.
    Interpretation and limitations
    Iron-deficiency anaemia or new alarm symptoms accelerates investigation. Normal bloods do not neutralise progressive dysphagia or a visible lesion.
    • 1
    Use high-resolution white-light endoscopy, clean the mucosa, document Prague measurements and examine carefully for nodules, ulcers, depressions or subtle pattern change.
  • 2Refer or manage every visible abnormality through an expert resection pathway; avoid ablating an uncharacterised lesion that may contain invasive cancer.
  • 3Take Seattle-protocol biopsies from the remaining flat mucosa in separately labelled levels according to the local quality-assured protocol.
  • 4Communicate histology, interval and symptom safety-net in writing, and audit missed protocols or delayed pathology follow-up.
    • 03DysplasiaConfirm and eradicate neoplasiaIndefinite, low-grade or high-grade dysplasia is reported.+
    1. 1Obtain expert GI pathology review and optimise acid-mediated inflammation; repeat expert endoscopy when the grade may be confounded or confirmation is required.
    2. 2For visible neoplasia, perform specialist endoscopic resection to stage depth and risk before selecting further ablation or surgery.
    3. 3Offer NICE-recommended radiofrequency ablation for qualifying confirmed low-grade dysplasia and specialist endoscopic eradication for high-grade disease or suitable T1a cancer.
    4. 4After eradication, continue the specialist post-treatment surveillance schedule because buried, recurrent or metachronous disease can occur.
    Key medicines and prescribing safety2 treatments · regimens, roles and cautions+
    Controls reflux symptoms and heals oesophagitis so mucosa and dysplasia can be assessed more reliably.

    Proton pump inhibitor for coexisting reflux

    Use a licensed full-dose PPI such as omeprazole 20 mg orally once daily for symptomatic GORD, adjusting to healing and the lowest effective maintenance dose under NICE and product guidance.

    Do not promise elimination of cancer risk or substitute medication for indicated surveillance. Review interactions and long-term need, and escalate dysphagia or bleeding rather than simply increasing the dose.

    Clarifies that antiplatelet therapy has no routine NICE-supported role purely for Barrett cancer prevention.

    Aspirin is not Barrett chemoprevention

    Do not start aspirin solely to prevent progression of Barrett oesophagus; if prescribed for another indication, use the evidence-based dose from that cardiovascular or specialist pathway.

    Aspirin can cause gastrointestinal bleeding and ulceration and interacts with anticoagulants and other antiplatelets. Continue or stop a separate cardiovascular indication only with the responsible prescriber.